国产AAV基因疗法登上Nature Medicine：安全有效治疗血友病，已获批上市

Core Viewpoint - The article discusses the development and clinical trials of BBM-H901, the first gene therapy for Hemophilia B in Asia, which shows promising safety and efficacy results for patients [4][9]. Group 1: Gene Therapy Development - BBM-H901 utilizes FIX-Padua, a high-activity variant of coagulation factor IX, delivered via an AAV vector targeting the liver, providing a new treatment option for Hemophilia B patients [3][4]. - The therapy was developed by a team led by Professor Xiao Xiao from East China University of Science and Technology and has been approved for market in China as "Xinjiao Ning" since April 10, 2025 [3]. Group 2: Clinical Trials - Initial Phase 1 trials involved 10 male patients, followed by a Phase 1/2 dose-escalation study with 6 patients and a Phase 3 confirmatory study with 26 patients to evaluate the efficacy of BBM-H901 [6]. - The Phase 1/2 study tested a dose of 5×10^12 vg/kg and achieved its primary endpoint without observing dose-limiting toxicities, with the most common adverse event being elevated transaminases (33.3%) [6][7]. Group 3: Efficacy Results - In the Phase 3 trial, the average annualized bleeding rate (ABR) dropped to 0.60 within 52 weeks post-infusion, significantly below the pre-defined efficacy threshold of 5.0 [7]. - The average FIX:C level from the AAV vector was 41.9 IU/dL at 52 weeks, with 80.8% of patients experiencing no bleeding during the follow-up period [7][9].